Detailansicht

InhaltsangabePrediction of Tumor Behaviour: Beyond typing and grading: target analysis in individualized therapy as a new challenge for tumour pathology. Oncogenic signaling pathways and deregulated target genes. Predictive pathology of cytostatic drug resistance and new anti-cancer targets. Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract. Resistance-associated signatures in breast cancer. Resistance to chemotherapy in ovarian carcinoma. Clinical, biological, and molecular aspects of metastasis in colorectal cancer. Prediction of efficacy and side effects of chemotherapy in colorectal cancer. Proteomic expression profiling of breast cancer.- Targeted Therapy and the Clinics: Targeted therapy and blood-brain-barrier. Cetuximab - appraisal of a novel drug against colorectal cancer. C-kit, GIST and Imatinib. Antibody therapy in non-Hodgkin's lymphoma: the role of rituximab, 90Y-ibritumomab tiuxetan and alemtuzumab. Molecular and clinical aspects of proteasome inhibition in the treatment of cancer. Individualizied targeted therapy of malignant lymphomas: an outlook. Antiangiogenesis, anti-VEGF(R) and outlook. Morphological detection of hormone and growth factor receptors in breast cancer. What's in the Pipeline: Antigen specific cancer vaccines. Therapeutic vaccination for the treatment of malignant melanoma. Monoclonal and recombinant antibodies with T cell receptor-like reactivity. New molecular therapy targets in acute myeloic leukemia.

Includes supplementary material: sn.pub/extras